Pharmafile Logo

payer survey

Let’s throw it against the wall and see what sticks…

Why including drug costs in DTC advertising is an idea full of holes

Big Pharma, Little Pharma

Evolution provides options for those firms that can’t be huge

- PMLiVE

AI UK – one year on

Are patients still cautiously embracing new healthcare tools?

- PMLiVE

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

- PMLiVE

Hancock’s ‘Tech Revolution’ for NHS to be limited by budgets

Vision for a tech-driven NHS unveiled, but is there money to fund it?

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

Gema Noguera

Porterhouse Medical rewards superb client service skills

Porterhouse Medical is delighted to announce the promotion of Gema Noguera to senior account director. Since joining the client services team as a senior account executive in 2013, Gema has...

Porterhouse Medical Group

- PMLiVE

Retaining reader value in plain language summaries of clinical studies

Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries

- PMLiVE

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?

Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Page & Page Health

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links